Taken together, our studies suggest that amlodipine suppresses GSCs-initiated tumor development via degrading EGFR and down-regulating its downstream pro-survival pathways, implying that amlodipine has novel potential as a therapeutic agent targeting GSCs in glioblastoma, deserving further investigations. The gene discussed is EGFR; the disease is neoplasm.